Trials / Recruiting
RecruitingNCT05493215
Imatinib TDM in GIST
A Phase 2 Study of Imatinib Therapeutic Drug Monitoring in Gastrointestinal Stromal Tumor
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Reema A. Patel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | Therapeutic drug level monitoring with plans to increase to adjust drug dosage based on levels and patient symptoms. |
Timeline
- Start date
- 2024-03-26
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2022-08-09
- Last updated
- 2026-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05493215. Inclusion in this directory is not an endorsement.